Insulin is a hormone that is essential for regulating energy storage and glucose metabolism in the body. Insulin in liver, muscle, and fat tissues stimulates the cell to take up glucose from blood and store it as glycogen in liver and muscle. Failure of insulin control causes diabetes mellitus (DM). Insulin is the unique medicine to treat some forms of DM. The population of diabetics has dramatically increased over the past two decades, due to high absorption of carbohydrates (or fats and proteins), lack of physical exercise, and development of new diagnostic techniques. At present, the two largest developing countries (India and China) and the largest developed country (United States) represent the top three countries in terms of diabetic population. Insulin is a small protein, but contains almost all structural features typical of proteins: α-helix, β-sheet, β-turn, high order assembly, allosteric T®R-transition, and conformational changes in amyloidal fibrillation. More than ten years' efforts on studying insulin disulfide intermediates by NMR have enabled us to decipher the whole picture of insulin folding coupled to disulfide pairing, especially at the initial stage that forms the nascent peptide. Two structural switches are also known to regulate insulin binding to receptors and progress has been made to identify the residues involved in binding. However, resolving the complex structure of insulin and its receptor remains a challenge in insulin research. Nevertheless, the accumulated knowledge of insulin structure has allowed us to specifically design a new ultra-stable and active single-chain insulin analog (SCI-57), and provides a novel way to design super-stable, fast-acting and cheaper insulin formulations for DM patients. Continuing this long journey of insulin study will benefit basic research in proteins and in pharmaceutical therapy.
INTRODUCTION
A sparrow may be a small bird, but it is fully equipped to act as a bird. Insulin, as a protein, can be viewed in a similar way: it is a small but fully functional protein. Insulin displays both key properties of naturally existing proteins: a stable structure and a physiologic function. On the one hand, insulin is one of smallest proteins of all known native functional proteins and it possesses most of the typical protein structural features: α-helix, β-sheet, β-turn, high order assembly, allosteric T®R-transitions and conformational changes by self-association, and amyloidal fibrillation (Blundell et al., 1971; Peking, 1971; Chothia et al., 1983; Baker et al., 1988; Derewenda et al., 1989; Dobson, 1999; Hua and Weiss, 2004; Huang et al., 2005 Huang et al., , 2006 . As a small protein, insulin is a good model for basic structural research, especially for studying protein folding intermediates with a variety of disulfide pairings. On the other hand, insulin plays a central role in the regulation of vertebrate metabolism, especially carbohydrate metabolism. The initial step in hormonal control is the specific binding of insulin to the insulin receptor (IR) (Baker et al., 1988; De Meyts, 1994; De Meyts and Whittaker, 2002) . Binding of insulin to its receptor triggers a series activation of tyrosine kinase. In the short term, insulin increases sugar transport and protein synthesis, inhibits lypolysis, activates enzymes (such as glycogen synthetase), and inactivates other antagonist-like enzymes (such as phosphorylase). In the long term, insulin activates glucokinase and suppresses gluconeogenesis enzymes. Although the hormone functions in the bloodstream as a Zn 2+ -free monomer (Dodson and Steiner, 1998) , insulin assembles as a Zn 2+ -coordinated hexamer in the human β-cell (Blundell et al., 1971 ). The hexamer is proposed to function as a protective mechanism preventing toxic fibrillation of insulin during in vivo storage. This sequestration of the susceptible monomer within the zinc hexamer (Brange et al., 1997a; Brange and Langkjaer, 1997 ) is exploited in clinical formulations (Brange, 1987) .
The transition of a globular domain to a well-organized cross-β fibril occurs in insulin fibrillation (Brange et al., 1997b) . Various mutations causing conformational changes impair receptor binding and consequently induce diabetes mellitus (DM). Diabetes occurs either because of a lack of insulin or due to insulin resistance. Recently, the number of diabetes patients has increased dramatically. The statistics data from the National Diabetes Fact Sheet showed that nearly 24 million Americans (~8% of the population) have diabetes (http://www.diabetes.org/diabetes-basics/diabetesstatistics/). An additional 57 million people are pre-diabetic and are not included in this total. Of these patients, 90% are type-II diabetics. The World Health Organization (WHO) stated that people diagnosed with diabetes have increased from 30 million to 246 million over the past two decades. The complications of diabetes include heart disease and stroke, high blood pressure, blindness, kidney disease, neuropathy and death. Diabetes is the seventh leading cause of death listed in the US.
The rapid development of human genetics enables scientists to identify more gene mutations related to diabetes, especially to permanent neonatal-onset DM. The positions of mutations in the proinsulin sequence are marked as black circles in Fig. 1A and 1B. (Støy et al., 2007; Colombo et al., 2008; Edghill et al., 2008; Molven et al., 2008) . The positions of adult-onset mutations ("classical mutations") are labeled as gray circles in Fig. 1A .
The insulin gene encodes a single-chain precursor polypeptide (preproinsulin) that contains a 24-residue signal peptide at the N-terminal (not shown in Fig. 1 ) and a 35-residue connecting domain (black in Fig. 1B ) between the Cterminal residue of the B domain (B1) and the N-terminus of the A domain (A1) (Steiner, 1967) . The C-peptide is cleaved by a specific prohormone convertase at conserved dibasic sites flanking the C domain (B-C and C-A junctions) (Steiner, 1998) . Although insulin acts in blood in the absence of the Cpeptide, newly identified mutations in neonatal-onset DM are found not only in insulin moiety, but also in the C-peptide or even in the signal peptide (24 residues) that is cleaved on translocation into the ER to yield proinsulin.
The Cys A7 ®Tyr mutant can be viewed as a model to investigate the relationship between misfolding and DM. As shown in Fig. 1A , a mutation of Cys A7 ®Tyr in permanent neonatal-onset DM is identical to that in the "Akita" mouse with native Type-II diabetes (Yoshioka et al., 1997; Wang et al., 1999; Oyadomari et al., 2002) . This A7-Cys mutation and all other Cys-mutations are predicted to block folding of the precursor in the endoplasmic reticulum (ER) of pancreatic β-cells. Studies of the Akita mouse model have demonstrated that misfolding of the various proinsulin forms perturbs the biosynthesis of wild-type insulin, and in turn, the apoptosis of β-cells (Wang et al., 1999; Oyadomari et al., 2002; Ron, 2002; Izumi et al., 2003) . These findings have restored interest again in the structural basis of disulfide pairing Qiao et al., 2001; Hua et al., 2006a, b; Qiao et al., 2006; Guo et al., 2008) . These models of impaired folding provide structural insight into a disease of toxic protein misfolding. However, they also raise questions, such as how insulin binds to its receptor, or why these mutations induce diabetes. The nature of the main underlying cause of diabetes-whether it is damage to the insulin-receptor specific binding or impairment of the proper conformation of insulin-is also unclear. Thus, to understand diabetes-related mutations, we have to interpret insulin structure in detail and reveal its structural-functional relationships.
Insulin is a globular protein containing two chains: the Achain consists of 21 residues, and the B-chain has 30 residues. The molecule is linked by three disulfide bridges (two inter-chain: A7-B7 and A20-B19, and one intra-A-chain: A6-A11). A variety of dimeric and hexameric crystal structures of insulin have been determined. Structures of insulin in different crystal forms (Blundell et al., 1971; Peking, 1971; Bentley et al., 1976; Baker et al., 1988; Derewenda et al., 1989; Badger et al., 1991; Ciszak and Smith, 1994) have provided a pioneering example of long-range conformational change in a protein (Fig. 1D ). Among these, Bake et al. (1988) described the insulin structure in monomer, dimer and hexamer forms in most detail-this paper could be called the "bible" of insulin structure. The T-state of the crystal structure of native insulin is shown in Fig. 1D . Allosteric T/Rtransition occurs in various crystal insulin forms; a dimer is shown in Fig. 1C . The N-terminal extended arm of the B-chain (B1-B8, right promoter) in the T-state changes to an α-helix and forms a long helix from B2 to B19 in the R-state (left promoter). To circumvent the self-association of insulin in solution, an engineered monomeric DKP-insulin was designed and used as a template for further mutation. In this monomer, HisB10®Asp prevents the formation of a hexamer and a switch of the B28Pro/B29Lys residues prevents dimerization contact Hua et al., 1996a Hua et al., , 2001b Hua et al., , c, 2009 ). In addition to X-ray crystallographic approaches, nuclear magnetic resonance (NMR) can be used as a complimentary technique to determine the three-dimensional (3D) solution structures for insulin, its analogs and other flexible, molten-globule-like proteins (Wuthrich, 1986) . Fig. 1E shows an ensemble of 20 NMR structures of DKP-insulin. All solution structures of insulin and its analogs in solution exhibit the T-state.
A large and ancestral family of insulin-related sequences has been discovered, including insulin, IGF-I (insulin-like growth factor-I), IGF-II, relaxin, bombyxin, C. elegans insulinlike peptide (ILP) and molluscan insulin-like peptide. In the insulin super-family, the sequence homology of Cys and the common "insulin fold" is shared (Humbel, 1990; Cooke et al., 1991; Eigenbrot et al., 1991; Murray-Rust et al., 1992; Sato et al., 1993; Torres et al., 1995; Nagata et al., 1995a, b; De Wolf et al., 1996; Gill et al., 1999; Sato et al., 2000; Hua et al., 2003) . Study of the insulin structure is important for interpreting insulin and DM as well as for understanding other members of the insulin superfamily. This review primarily focuses on the structure of insulin and its analogs.
STRUCTURAL FEATURES
Hydrophobic core and ordered secondary structure Despite its small size, insulin contains representative structural features of larger proteins, including a well-ordered hydrophobic core and canonical elements of secondary structure (Baker et al., 1988) . As shown in Fig. 1 , the solution structure of insulin (E) resembles the crystal T-state structures of insulin in various crystal forms (D): three helices (B9-B19, A2-A8 and A13-A19, designated as helix-1, -2 and -3), two β-turns (B7-B10 and B20-B23) and one β-strand (B24-B28).
The hydrophobic core of insulin is composed of four structural elements: the central helix of B-chain (B9-B19), a mostly buried disulfide bridge (A20-B19), the C-terminal helix of the A-chain (A13-A19) and a β-turn at B20-B23. This β-turn allows the C-terminal β-strand segment to pack against the central helix of the B-chain (Bao et al., 1997; Hua et al., 2001 Hua et al., , 2006b ). As described above, three helices form the major body in the insulin structure and make insulin a helical rich protein. Of these helices, the A2-A8 helix is not well folded like other two helics (Baker et al., 1988; Hua et al., 1996a Hua et al., , b, 2002a . Insulin is a molten-globule like small protein in some situations, as observed by NMR and other biophysical chemical methods (Hua et al., 1992a) .
Three disulfide bridges
Three disulfide bridges (A6-A11, A7-B7, and A20-B19) are "framework" in all members of the insulin family. These bridges (shown in gold in Figs. 1D and 1E) play a critical role for protein stability and biological activity Dai and Tang, 1996; Hua et al., 1996a; Hober et al., 1997; Weiss et al., 2000; Feng, 2001, 2003; Jia et al., 2003; Yan et al., 2003; Hua et al., 2006b ). The structure, stability, and receptor binding activity of insulin require appropriate maintenance of each disulfide bridge Dai and Tang, 1996; Hua et al., 1996a; Weiss et al., 2000; Guo and Feng, 2001; Feng et al., 2003; Jia et al., 2003; Yan et al., 2003; Hua et al., 2006b) . The cystine provides interior struts in the hydrophobic core (A19-B20 and A6-A11) and an external staple between chains (A7-B7). Although the (A6-A11) and (A20-B19) disulfide bridges are both buried, the crystal and NMR structural studies indicate that the (A6-A11) bridge is relatively flexible and poorly ordered, whereas the (A20-B19) bridge presumably stabilizes the entire molecule. The exposed (A7-B7) bridge restrains the two N-terminals of the A-and B-chain like a special staple. Mutation at any Cys dramatically impairs receptor binding and destroys the conformation, so that the yield of biosynthesis and chain combination is normally quite low or even undetectable (such as deletion of A20-B19 bond).
Two structural switches and a Gly B8 related allosteric
T®R transition
When insulin binds to its receptor, a conformational change of insulin occurs at the positions of two structural switches. Analysis of a single insulin chain linked by a B29-A1 covalent bond reveals that it is completely inactive (Derewenda et al., 1989 (Derewenda et al., , 1991 . However, Fig. 2A shows that the structure of mini-proinsulin is nearly identical to the native T-state insulin ( Fig. 1D ), which implies that when the C-terminal of the B-chain is "closed" against the central helix of the B-chain, this represents the "inactive" conformation. The crystal form of insulin seems to be a "dead" structure, suggesting that insulin conformation must change upon receptor binding (Derewenda et al., 1991; Liang et al., 1992) . The NMR structure of Gly B24 -insulin provided the first experimental evidence for this hypothesis (Hua et al., , 1992b . A Phe to Gly substitution at position B24 is tolerant to receptor binding, and it retains as high as 80% of the binding activity of native insulin. Its structure is "opened" at the C-terminal of the B-chain (Fig. 2C ). Fig. 2 shows that the "closed" B-chain at the native state is "inactive", whereas the "opened" B-chain may represent an active state. The B24 Phe plays an important role in the structural switch. The "open" state, in which the side-chain of the A2 Ile and A3 Val are exposed from their hidden position, enables key residues of the receptor to bind to the A2 and A3 residues (Nanjo et al., 1986; Steiner et al., 1990; Nakagawa and Tager, 1992; Hua et al., 2002a; Huang et al., 2007) . Chiral mutagenesis at B24 by substitution of D-Ala or L-Ala further demonstrated that the conserved side chain of Phe B24 is an anchor for the B24-B28 strand; its substitution by Ala (Fig. 3A) leads to an unstable but native-like analog of low activity (~4% of native insulin). However, D-Ala substitution is equally unstable but exhibits enhanced activity (2-fold affinity) relative to insulin, with segmental unfolding of the β-strand as shown in Fig. 3B (Hua et al., 2009 ). The Phe B24 and adjoining B20-B23 β-turn is required for functional activity (Bao et al., 1997) . A bifunctional β-strand B24-B28 mediates both selfassembly (within β-cell storage vesicles) and receptor binding (in the bloodstream).
Another structural switch is Gly B8 , which is a conserved residue in all species with a positive f dihedral angle. While any L-substitution at B8 impairs chain combination, the corresponding D-substitution enhances yield (Nakagawa et al., 2005; Hua et al., 2006c) . A stereospecific modification of the structural switch B8 implies that this type of "chiral mutagenesis" blocks receptor binding of the D-analog, but retains the "native state" structure of insulin. The D-Ser substitution enhances stability, but impairs receptor binding by 100-fold; whereas the L-Ser substitution remarkably impairs stability with only 2-fold reduction in receptor binding. Similarly, while D-Ala at B8 "locks" insulin conformation into the T-state and causes only 0.1% affinity, L-Ala-substitution "rescues" receptor binding as high as 20 folds (Nakagawa et al., 2005; Hua et al., 2006c) . The sign of the B8 f angle possibly contributes to the alignment or misalignment of the neighboring Cys B7 for disulfide pairing (Baker et al., 1988; Adams et al., 2000) . About 20 years ago, B6 Leu was reported to possibly participate in receptor binding (Nakagawa and Tager, 1991) . Replacement of Leu B6 by Gly has a nearly equivalent effect as deletion of residues B1-B6 in decreasing receptor binding potency (to only 0.05% of insulin). Ala scanning also revealed that replacement impairs binding (Kristensen et al., 1997) . This suggests that the position of B6 might undergo some movement during receptor binding. The T®R transition has been proposed as a model for insulin's active conformation (Nakagawa et al., 2005) . D-amino acids at B8 would thus favor the T state whereas L substitutions would favor the R state. The T®R transition is an allosteric feature of the zinchexamer assembly. Gly B8 related T®R transition exploits the intrinsic flexibility of Gly B8 . Therefore, both N-and C-terminal segments of the B-chain would be expected to reorganize receptor binding and the crystallographic T®R transition in part represents how the insulin monomer changes conformation upon receptor binding. It is reasonable to speculate that a B8 switch related T®R transition is required for receptor binding.
Inter-chain hydrogen bond
As a small protein, insulin is stabilized by bulk and subtle weak interactions, such as hydrogen bonding and Van der Waals contact. Among these, inter-chain hydrogen bonds in insulin are important for proper folding, such as those at A6 CO-B6 HN, A7 CO-B5HeN, A11 HN-B4 CO, A19 CO-B25 HN and A21 HN-B23 CO. The NMR structure of the depsi-insulin (B24-B25 CO-O) with native sequence and a B24-B25 ester bond (Kurapkat et al., 1997 ) maintains a structure similar to that of native insulin, but it retains only 3%-4% potency. This modification breaks the H-bond between the amide proton of B25 and the carbonyl oxygen of A19. The crystal structure studies of Asn A21 substituted by Gly, Ala, Asp and Gln revealed the conformational correlation and the coupled motion between residues in the A21 and B25 side chains, respectively (Zeng et al., 2000) . Invariant residue A21 may affect receptor binding. The lack of a hydrogen bond between B25 and A19 or the replacement of A21 both affect the position of the B25 Phe side chain and consequently impair receptor binding. The hydrogen bond A21-B23 and the local B25 environment are sensitive for receptor binding. Actually, a few invertebrate insulin-like peptides (such as β-subfamily in C. elegans ILP) contain a fourth disulfide bond (A21-B23), which is interesting in terms of the evolution of insulin (Duret et al., 1998; Pierce et al., 2001; Hua et al., 2003) . Mutational sites His B5 and Gly B8 (both broadly conserved among vertebrate insulins) have been well characterized (Nakagawa et al., 2005; Hua et al., 2006a, c; Wan et al., 2008) . His B5 is an important neighbor residue of B8. The solution structure of the Ala B5 insulin analog retains native features and exhibits substantial biological activity (129% relative to native insulin) despite its reduced foldability ( < 10% yield relative to wild-type insulin), which implies that His B5 is not directly involved in receptor binding but significantly affects the yield of insulin (Hua et al., 2006a exists in some non-mammalian such as coypu or rabbit fish. Both these His and Arg residues contain side-chain NH groups. An important difference between structures of Ala B5 -DKP-insulin and its template DKP-insulin is the existence of an H-bond between the B5 His imidazole proton and the A7 (or A9) carbonyl oxygen in DKP-insulin. It seems that formation of a disulfide bridge (A7-B7) in insulin is difficult without this hydrogen bond. This hypothesis has lately been proved by the observation that the crystal structure of Arg B5 -insulin contains a B5-A7 hydrogen bond (Wan et al., 2008) . Thus, in the native state, His B5 can be proposed to pack within an inter-chain crevice, changing one or more hydrogen bonds to carbonyl oxygens in the A chain. Substitution of His B5 by diverse side chains impairs disulfide pairing in chain combination (Hua et al., 2006a) ,whereas Arg B5 is well tolerated, presumably because of formation of analogous inter-chain hydrogen bonds (B5-A7) (Wan et al., 2008) . Substitution of His B5 by Asp in mammalian cell culture blocks the folding and secretion of human proinsulin (Hua et al., 2006a ). Other inter-chain H-bonds (B6-A6 and A11-B4) may also contribute to the formation of the A7-B7 disulfide bond.
FOLDING: DISULFIDE PAIRING VS. CORRECT FOLDING
From the chemical aspect, a protein is a linear heteropolymer. Protein folding has been intensively studied over the last three decades, since Anfinsen's famous assumption proposed that the native structure of a protein is uniquely determined by its linear amino acid sequence (Anfinsen, 1973) . Protein folding study is important for both basic research and in the pharmaceutical industry. The structure of folding intermediates is difficult to solve due to their short "life time" and easy aggregation. Furthermore, for Cys-containing proteins, the appropriate folding is always coupled with correct disulfide pairing. Air oxidation of isolated A-and B-chains of insulin preferentially yields insulin with correct disulfide pairing (Du et al., 1965; Katsoyannis and Tometsko, 1966; Zahn and Schmidt, 1967) . In each case, oxidative refolding of proinsulin and insulin chain combinations utilizes similar native disulfide pairing (Tang and Tsou, 1990; Wang and Tsou, 1991) . The folding pathway of insulin or its single chain analog PIP (Porcine Insulin Precursor with Ala-Lys di-peptide linker between B30 and A1) reveals certain folding intermediates with different disulfide pairings (Milner et al., 1999; Qiao et al., 2001 Qiao et al., , 2003 Yan et al., 2003) . Oxidative refolding of proinsulin or chain combination of insulin yields only the native disulfide pairing scheme (Hua et al., 2006b ); however, human IGF-I refolds to form two products: one native IGF-I (~60%) and the other with a specific disulfide-swap (~40%). The two isomers are in thermodynamic equilibrium Narhi et al., 1993; Hua et al., 1995 Hua et al., , 1996b . Because these folding intermediates are difficult to crystallize, NMR is an alternative approach to solve or mimic the solution structure of these intermediates. Insulin and IGF-I exhibit stepwise acquisition of structures with successive formation of one, two and three disulfide bridges Hua et al., 2001) . The model disulfide intermediates of insulin (or IGF-1) with different disulfide bonds are listed in Table 1 .
Three disulfide insulin isomers: insulin disulfide isomer-I and -II
The formation of insulin folding isomers with three disulfides can be induced by disulfide exchange in dithiothreitol (DTT) with Guanidine-HCl (Hua et al., 1995 (Hua et al., , 2002b . The products of disulfide reassortment in the denatured condition are isomer-I (insulin-swap-1, Fig. 4A ) and isomer-II (insulin-swap-2, Fig. 4B ), both of which retain the native A20-B19 disulfide. Swap-1 contains (A6-B7 and A7-A11) disulfides while swap-2 contains (A6-A7 and A11-B7) disulfides, as listed in Table 1 . While the main structural feature of native insulin is retained in swap-1 with movement of N-terminal of B-chain, the structure is much less ordered in swap-2, which coincides with a 3.9 kcal/mol reduction in denatured stability relative to native insulin (Hua et al., 2002b) . The two N-terminal "arms" of insulin exhibit high flexibility, with only one "staple" existing between A11 and B7 (Fig. 4B) . The NMR structure of IGF-Iswap exhibits a similar pattern to that of insulin-swap-I (Sato et al., 2000) . The pre-fibril solution structure of insulin (Fig. 4C ) maintaining three disulfide bonds was obtained under amyloidogenic conditions (pH 2.4 and 60°C). A novel partial fold is observed similar to swap-2 (Fig. 4B) . The N-terminal segments of both chains of insulin detach from the core (Hua and Weiss, 2004) . Unfolding of the N-terminal α-helix of the A-chain exposes a hydrophobic surface but maintains native-like packing, including the remaining parts of the α-helices. The C-terminal segment of the B-chain, although not well ordered, remains partially tethered to this "shrunken" helical core.
Two disulfide insulin isomers: pair-substitution of Cys®Ala (or Ser)
Two disulfide isomers of insulin exhibit molten-globule structures of marginal stability and low biological activity (Sieber et al., 1978; Hua et al., 1995 Hua et al., , 2002b (Hua et al., 1996a (Hua et al., , b, 2001 Weiss et al., 2000) .
The solution structure of Ser substitution at A6 and A11 in insulin (Fig. 4G ) and in IGF-I is remarkable for segmental unfolding of the N-terminal A-chain α-helix (A2-A8) in an otherwise native sub-domain (Hua et al., 1996a, b) . The A6-A11 disulfide bridge is buried and surrounded by hydrophobic residues in native insulin. The preference to form a helix in the N-terminal segment makes it possible to dock into the "internal template" by a hydrophobic interaction, and consequently, the A2-A8 helix formation may help to link the disulfide bridge at A6-A11. The Ala-substituted analog retains the same structure as the Ser analog (Fig. 4H ) (Weiss et al., 2000) . Intriguingly, the structure of Ser A7, B7 -DKP-insulin changed dramatically (Fig. 4I) , and the most exposed disulfide A7-B7 in native insulin was broken (Hua et al., 2001) . Circular dichroism (CD) and NMR results indicate that this intermediate model retains a much less well-defined secondary structure than that of the above models. In comparison to insulin swap-2, its two N-terminal "arms", without the "staple" between A7 and B7, (Fig. 4I ) exhibit even higher flexibility (Fig. 4B) .
A one-disulfide IGF-I analog: a folding nucleus
An insulin analog with only one disulfide bond (A20-B19) is rarely synthesized because of its easy aggregation and extremely low yield during chain combination. To mimic a onedisulfide bond model, a corresponding one-disulfide IGFanalog was prepared, which contains only 37 residues with an 18-61 disulfide bridge (corresponding to A20-B19 in insulin) (Hua et al., 2006b ). This one-disulfide-linked IGF-I analog is not well ordered. However, NMR spectra illustrate the existence of nascent helical elements corresponding to native α-helices and establishes transient formation of a native-like partial core, suggesting that early events in the folding of insulin-related polypeptides are nucleated by a native-like molten subdomain containing a (A20-B19) bridge. The intermediate studies of insulin (and IGF-I) are summarized by structural models in Fig. 4 , in which a folding nucleus is shown in the middle. In spite of the conformational differences among a number of the intermediates in Fig. 4 , one structural feature always remains: the structural motif (also referred to as the super-secondary structure) as shown in Fig. 4E , which consists of two helices: B9-B19 and A13-A19 helix (or even a short helix of A17-A20), one disulfide bridge (A20-B19), and an adjoining B23-B26 segment that folds back against the central B-chain. We speculate that this super-secondary structure is the "folding nucleus". Cystine A20-B19 is the unique one-disulfide species to accumulate in the refolding of mini-proinsulin and IGF-I (Miller et al., , 1999 Qiao et al., 2001) , and thus, it is proposed to contribute to the stabilization of a specific folding nucleus (Hua et al., 1996b (Hua et al., , 2001 (Hua et al., , 2006b ). The intrinsic conformational characteristics of the flexible disulfide-linked peptide define the folding nucleus, foreshadowing the structure of the native state. Folding can proceed after A20-B19 pairing through multiple alternative channels, including on-pathway intermediates and off-pathway kinetic trapping (see reference (Hua et al., 2001; Qiao et al., 2001; Yan et al., 2003; Hua et al., 2006b ) for a detailed discussion). This disulfide bridge packs within a cluster of conserved aliphatic and aromatic side chains in the hydrophobic core (Hua et al., 1995 (Hua et al., , 2002a . As successive disulfide bridges are introduced into the above models, NMR spectra exhibit progressively increased chemical-shift dispersion, suggesting stepwise stabilization of structure.
BINDING WITH THE INSULIN RECEPTOR
How insulin binds to its receptor is still unknown, despite decades of investigation. Insulin's active conformation and how it relates to the classical crystal structures of insulin is not yet clear, nor are the points of contact between insulin and the insulin receptor (IR). Whether insulin binding triggers the reorganization of the ectodomain of the IR also remains to be established. The best answer to these questions would come from determining the structure of the complex of insulin and its receptor. However, this complex has not yet been characterized, either by X-diffraction or by NMR.
Structure of the insulin receptor
The insulin receptor and the IGF-I receptor belong to the superfamily of receptor tyrosine kinases. To date, the crystal structure of the IR ectodomain in Fig. 5 provides the highest resolution for the IGF-I structure, which seems different from that of the EGFR, especially in the regions governing ligand specificity (See details in references McKern et al., 2006; Lawrence et al., 2007; Ward et al., 2008) ).
Insulin-receptor binding surface
There are two ways to identify the residue proposed for receptor binding: an alanine scan (and other site-directed mutagenesis by other residues) (Kristensen et al., 1997) and photo cross-linking (Kurose et al., 1994) . While alanine scanning mutagenesis has been systematically used to identify specific side chain of insulin (Kristensen et al., 1997) , the photo cross-linking method directly reveals the contacts between specific residues of insulin and its IR binding points (Huang et al., 2004; Xu et al., 2004a Xu et al., , b, 2009 . To determine the contact between insulin and IR by a photo cross-linking method, insulin analogs containing a photo-activatable derivative of phenylalanine, para-azidoPhe (Pap, Fig. 5C ), were first synthesized (Kurose et al., 1994) . The α-amino group of the B-chain is biotinylated to enable efficient detection of cross-linked peptides (Kurose et al., 1994; Huang et al., 2004; Xu et al., 2009) . In addition to the identification of insulin residues for binding, the resulting cross-linked peptide fragments can be separated by affinity chromatography and sequenced; consequently, some of the smallest identified fragments in the α-subunit of IR have been analyzed (Kurose et al., 1994; Xu et al., 2009 ). Interestingly, a recent report shows that insulin inserts a detachable arm between receptor domains. For residues in the insulin B-chain β-strand segment, even-numbered probes (at positions B24 and B26) contact the N-terminal L1 domain of the α-subunit, while odd-numbered probes (at positions B25 and B27) contact its C-terminal insert domain ).
Models of the insulin receptor binding surface have been extended to define two distinct clusters of contact residues. The major (or classical) receptor binding surface (Pullen et al., 1976) (De Meyts and Whittaker, 2002) , whereas the accessory surface is proposed to contain Leu A13 and Leu B17 (De Meyts, 1994; Schäffer, 1994; De Meyts and Whittaker, 2002) . One ligand would appear to serve as a cross-link between two subunits within the α 2 β 2 heterotetramer (Fig. 5B ).
Induced fit of insulin on receptor binding
As discussed above, two structural switches exist in the insulin structure. "Chiral mutagenesis", which compares matched D-and L-amino-acid substitutions at sites, reveals induced fitting at B8 or B24. A conserved residue Phe B24 is involved in receptor binding since its substitution by D-Phe or D-Ala enhances insulin activity (Kobayashi et al., 1982; Shoelson et al., 1992) , whereas GlyB8 is not directly involved in binding, but seems indirectly involved in binding via crystallographic T®R transition. The side chain of Leu B6 is buried in the T state, but might be exposed on a change in configuration of Gly
B8
. The activity of D-Ala B8 analogs is the lowest among known analogs of native-like structure. The minimal photo-cross-linking properties of a low-affinity Dpara-azido-Phe B8 analog suggests that the impaired activity of D analogs is due to "locking" of the B8 f dihedral angle and prevention of binding of the D-side chain to the receptor. At the ostensibly unrelated processes of disulfide pairing, allosteric assembly and receptor binding appear to utilize the same residue as a structural switch: an "ambiguous" B8 glycine unhindered by the chiral restrictions of the Ramachandran plane.
However, it is still not clear which state insulin adopts when it binds to its receptor. The NMR structure and stability analysis of D-Ala B8 -and D-Ser B8 -DKP-insulin imply at least that insulin is not in the T-state when binding.
STABILITY AND FLEXIBILITY Fibrillation and misfolding
Stability is required for correct folding, whereas flexibility is required for receptor binding, especially for structural switches. However, misfolding is an unstable state with elevated flexibility that favors fibril formation. Protein fibrillation (Anfinsen, 1973; Cohen, 1999; Dobson, 1999 ) is a misfolding process of both fundamental and medical interest. As described above, folding intermediates easily undergo misfolding-coupled aggregation (Fig. 4 ) and insulin will be in the pre-fibril state (Fig. 4C ) in some conditions, such as in the presence of urea, guanidine, co-solvents (such as ethanol), hydrophobic surfaces, stirring and high temperature (Nielsen et al., 2001; Ahmad et al., 2003) . Protein fibrillation, which is a cytotoxic process of broad structural interest, is recognized as a mechanism of disease, including diverse amyloidoses and prion-associated encephalopathies (Dobson, 1999; Bucciantini et al., 2002) . As a classical amyloidogenic protein, insulin provides a good model (Waugh, 1941 (Waugh, , 1944 (Waugh, , 1946a (Waugh, , 1946b . Fibrillation is promoted by factors that destabilize the classical self-association pathway from monomer ® dimer ® tetramer ® hexamer ® higher-order native assemblies, presumably by increasing the availability of the susceptible monomer (Brange and Langkjaer, 1997) . Insulin is a helix-rich protein; therefore, it is a good example of the canonical transition of an α-helix to a cross-β-structure, as observed in amyloid diseases and prions (Laws et al., 2001) . Under conditions that promote the rapid fibrillation of zinc-free insulin, proinsulin is refractory to fibrillation. The connecting peptide, although not well ordered in native proinsulin, participates in a fibril-specific β-sheet (Huang et al., 2005) . The B30-A1 tethered mini-proinsulin impedes the fiber-specific α®β transition, leading to slow formation of a structurally non-uniform amorphous precipitate. Whereas native insulin exhibits pairings (A6-A11, A7-B7 and A20-B19), metastable isomers with alternative pairings (A6-B7, A7-A11 and A20-B19, or A6-A7, A11-B7 and A20-B19) readily undergo fibrillation with essentially identical α®β transitions (Huang et al., 2006) . Acid-induced "molten" features might also possibly increase the concentration of a putative fibrillogenic intermediate.
Design of new active ultra-stable insulin analog
Development of commercially used insulin has to consider the compensation between structural stability and receptor binding. Two commercially used insulin analogs are Humalog (Lys B28 and Pro B29 -insulin, from Eli Lilly) and Novalog (Asp B28 -insulin, from Novo-Nordisk) (Vajo and Duckworth, 2000) ; however, both of these were delayed from reaching the market for several years due to enhanced propensity for fibrillation. Recently, an active ultra-stable single-chain insulin analog (SCI-57) has been successfully designed (Hua et al., 2008) . SCI-57 contains a total of 57 residues with a sixresidue linker (GGGPRR). Its native receptor binding affinity (129% relative to wildtype) is achieved, as hindrance by the linker is offset by favorable substitutions in the insulin moiety with a Thr A8 ®His substitution. The thermodynamic stability of SCI-57 is markedly increased (DDG u 0.7 kcal/mol relative to the corresponding 57 residues two-chain analog and DDG u 1.9 kcal/mol relative to wild-type insulin). The design and structural model are shown in Fig. 6 . A new six-residue (GGGPRR) linker is favored for suitable balance between stability and flexibility in C-A junction of proinsulin: three Gly residues are quite flexible and Pro34 enables the linker twist, and the following two Arg are similar to conserved dibasic sites in the C-A junction of proinsulin. Neither longer nor shorter linkers are favored for proper stability and flexibility. In addition to their biophysical interest, ultra-stable SCIs may enhance the safety and efficacy of insulin replacement therapy in the developing world, where no refrigerator may be available to store insulin (Hua et al., 2008) . Based on the results of insulin study, the design of a new insulin analogs for commercial use is desired by numerous diabetes patients.
FOOTNOTE
Chinese scholars have made great contributions to the study of insulin at different stages. Recently, Prof. Youshang Zhang reminisced about the total synthesis of crystalline insulin by a Chinese group 50 years ago (Zhang, 2010) . Prof. Dacheng Wang provided a retrospective of the determination of insulin's crystal structure by Chinese crystallographers 40 years ago (Wang, 2010) and Prof. Youming Feng summarized recent important contributions on the structure-function and folding study of insulin (Feng, 2010) . A review paper of folding, binding, and stability of insulin can be seen in reference (Hua, 2004) . 
